logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out | Journal Article / Review | MSF Science Portal
Journal Article
|Review

Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out

Letang E, Ellis J, Naidoo K, Casas EDT, Sanchez P, Hassan-Moosa R, Cresswell F, Miro JM, Garcia-Basteiro AL
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.

Subject Area

tuberculosisHIV/AIDS

Languages

English
DOI
10.1016/j.arbres.2019.11.015
Published Date
01 Jul 2020
PubMed ID
31932150
Journal
Archivos de Bronconeumologia
Volume | Issue | Pages
Volume 56, Issue 7, Pages 446-454
Issue Date
2020-07-01
Dimensions Badge